|
1
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fukuoka M, Yano S, Giaccone G, Tamura T,
Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S,
Rischin D, et al: Multi-institutional randomized phase II trial of
gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J lin
Oncol. 21:2237–2246. 2003.[corrected]. View Article : Google Scholar
|
|
3
|
Kris MG, Natale RB, Herbst RS, Lynch TJ
Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H,
Sandler A, et al: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: A randomized trial. JAMA.
290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sato M, Shames DS, Gazdar AF and Minna JD:
A translational view of the molecular pathogenesis of lung cancer.
J Thorac Oncol. 2:327–343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cohen MH, Williams GA, Sridhara R, Chen G,
McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R,
et al: United States Food and Drug Administration Drug Approval
summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res.
10:1212–1218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Errihani H, Inrhaoun H, Boukir A, Kettani
F, Gamra L, Mestari A, Jabri L, Bensouda Y, Mrabti H and
Elghissassi I: Frequency and type of epidermal growth factor
receptor mutations in Moroccan patients with lung adenocarcinoma. J
Thorac Oncol. 8:1212–1214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fakhruddin N, Mahfouz R, Farhat F, Tfayli
A, Abdelkhalik R, Jabbour M, Yehia L, Mahfoud Z and Zaatari G:
Epidermal growth factor receptor and KRAS mutations in lung
adenocarcinoma: A retrospective study of the Lebanese population.
Oncol Rep. 32:2223–2229. 2014.PubMed/NCBI
|
|
12
|
Sonobe M, Kobayashi M, Ishikawa M, Kikuchi
R, Nakayama E, Takahashi T, Menju T, Takenaka K, Miyahara R, Huang
CL, et al: Impact of KRAS and EGFR gene mutations on recurrence and
survival in patients with surgically resected lung adenocarcinomas.
Ann Surg Oncol. 19(Suppl 3): S347–S354. 2012. View Article : Google Scholar : PubMed/NCBI
|
